
Frankie L. Stinson
Examiner (ID: 8117)
| Most Active Art Unit | 1746 |
| Art Unit(s) | 1792, 1711, 2402, 1746, 2899, 3405, 1743 |
| Total Applications | 3621 |
| Issued Applications | 3013 |
| Pending Applications | 138 |
| Abandoned Applications | 470 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16206505
[patent_doc_number] => 20200239495
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => NOVEL 2-CARBOXYPENAM COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING NOVEL 2-CARBOXYPENAM COMPOUND OR SALT THEREOF, AND APPLICATIONS THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/839563
[patent_app_country] => US
[patent_app_date] => 2020-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37829
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 444
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16839563
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/839563 | 2-carboxypenam compound or salt thereof, pharmaceutical composition containing novel 2-carboxypenam compound or salt thereof, and applications thereof | Apr 2, 2020 | Issued |
Array
(
[id] => 16506151
[patent_doc_number] => 20200385407
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-10
[patent_title] => COMPOUNDS, CONJUGATES, AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/839064
[patent_app_country] => US
[patent_app_date] => 2020-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 89829
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16839064
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/839064 | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof | Apr 1, 2020 | Issued |
Array
(
[id] => 17640574
[patent_doc_number] => 20220168312
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => MULTICOMPONENT CRYSTAL FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 17/600860
[patent_app_country] => US
[patent_app_date] => 2020-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8574
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17600860
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/600860 | MULTICOMPONENT CRYSTAL FORMULATIONS | Apr 1, 2020 | Abandoned |
Array
(
[id] => 17292182
[patent_doc_number] => 20210388021
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => POLYPODOSIDE SWEET FLAVOR MODIFIER
[patent_app_type] => utility
[patent_app_number] => 17/291814
[patent_app_country] => US
[patent_app_date] => 2020-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21643
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17291814
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/291814 | Polypodoside sweet flavor modifier | Mar 31, 2020 | Issued |
Array
(
[id] => 16296157
[patent_doc_number] => 20200281880
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-10
[patent_title] => INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA
[patent_app_type] => utility
[patent_app_number] => 16/836870
[patent_app_country] => US
[patent_app_date] => 2020-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20987
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16836870
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/836870 | Inactivators of toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria | Mar 30, 2020 | Issued |
Array
(
[id] => 16267404
[patent_doc_number] => 20200268891
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-27
[patent_title] => Pharmaceutical Compositions Having Improved Storage Stability
[patent_app_type] => utility
[patent_app_number] => 16/834565
[patent_app_country] => US
[patent_app_date] => 2020-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11738
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16834565
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/834565 | Pharmaceutical compositions having improved storage stability | Mar 29, 2020 | Issued |
Array
(
[id] => 16628650
[patent_doc_number] => 20210047303
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-18
[patent_title] => ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/833020
[patent_app_country] => US
[patent_app_date] => 2020-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13322
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16833020
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/833020 | Alkyne substituted quinazoline compound and methods of use | Mar 26, 2020 | Issued |
Array
(
[id] => 16421867
[patent_doc_number] => 20200347065
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-05
[patent_title] => SALTS OF TAM INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/823751
[patent_app_country] => US
[patent_app_date] => 2020-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28627
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16823751
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/823751 | Salts of TAM inhibitors | Mar 18, 2020 | Issued |
Array
(
[id] => 18302853
[patent_doc_number] => 11624751
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-11
[patent_title] => Biomarkers for vitiligo
[patent_app_type] => utility
[patent_app_number] => 16/823085
[patent_app_country] => US
[patent_app_date] => 2020-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 4
[patent_no_of_words] => 52648
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 136
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16823085
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/823085 | Biomarkers for vitiligo | Mar 17, 2020 | Issued |
Array
(
[id] => 18172645
[patent_doc_number] => 11572341
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-02-07
[patent_title] => Biguanide compound and use thereof
[patent_app_type] => utility
[patent_app_number] => 16/820860
[patent_app_country] => US
[patent_app_date] => 2020-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14865
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 214
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16820860
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/820860 | Biguanide compound and use thereof | Mar 16, 2020 | Issued |
Array
(
[id] => 17435887
[patent_doc_number] => 11261199
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-01
[patent_title] => Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
[patent_app_type] => utility
[patent_app_number] => 16/818388
[patent_app_country] => US
[patent_app_date] => 2020-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 7268
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16818388
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/818388 | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies | Mar 12, 2020 | Issued |
Array
(
[id] => 16312288
[patent_doc_number] => 20200291026
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/818125
[patent_app_country] => US
[patent_app_date] => 2020-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23758
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -54
[patent_words_short_claim] => 317
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16818125
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/818125 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | Mar 12, 2020 | Abandoned |
Array
(
[id] => 16156455
[patent_doc_number] => 20200216460
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-09
[patent_title] => CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/818033
[patent_app_country] => US
[patent_app_date] => 2020-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5297
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16818033
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/818033 | Crystalline forms of therapeutic compounds and uses thereof | Mar 12, 2020 | Issued |
Array
(
[id] => 16310780
[patent_doc_number] => 20200289518
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => METHOD FOR TREATING BRAIN OR NERVE INJURY
[patent_app_type] => utility
[patent_app_number] => 16/816870
[patent_app_country] => US
[patent_app_date] => 2020-03-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13015
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16816870
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/816870 | Method for treating brain or nerve injury | Mar 11, 2020 | Issued |
Array
(
[id] => 16310702
[patent_doc_number] => 20200289440
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => Use of Formin Agonists in Overcoming Brain Tumor Radio- and Chemo-resistance by Targeting Tumor Microtubes
[patent_app_type] => utility
[patent_app_number] => 16/814425
[patent_app_country] => US
[patent_app_date] => 2020-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8913
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16814425
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/814425 | Use of formin agonists in overcoming brain tumor radio- and chemo-resistance by targeting tumor microtubes | Mar 9, 2020 | Issued |
Array
(
[id] => 17783536
[patent_doc_number] => 11406640
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-08-09
[patent_title] => JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
[patent_app_type] => utility
[patent_app_number] => 16/810045
[patent_app_country] => US
[patent_app_date] => 2020-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12942
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810045
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/810045 | JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction | Mar 4, 2020 | Issued |
Array
(
[id] => 17938350
[patent_doc_number] => 11472791
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-18
[patent_title] => Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/809218
[patent_app_country] => US
[patent_app_date] => 2020-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 21
[patent_no_of_words] => 70753
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 4086
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16809218
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/809218 | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors | Mar 3, 2020 | Issued |
Array
(
[id] => 16267266
[patent_doc_number] => 20200268753
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-27
[patent_title] => PERK AND IRE-1A INHIBITORS AGAINST NEURODEVELOPMENTAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/808724
[patent_app_country] => US
[patent_app_date] => 2020-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20057
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16808724
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/808724 | PERK AND IRE-1A INHIBITORS AGAINST NEURODEVELOPMENTAL DISORDERS | Mar 3, 2020 | Abandoned |
Array
(
[id] => 16090239
[patent_doc_number] => 20200199106
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-25
[patent_title] => COMPOUND FOR INHIBITING AND DEGRADING TYROSINE PROTEIN KINASE ALK
[patent_app_type] => utility
[patent_app_number] => 16/808333
[patent_app_country] => US
[patent_app_date] => 2020-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9378
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 935
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16808333
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/808333 | Compound for inhibiting and degrading tyrosine protein kinase ALK | Mar 2, 2020 | Issued |
Array
(
[id] => 16756553
[patent_doc_number] => 10975090
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-04-13
[patent_title] => Crystalline forms of therapeutic compounds and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/806819
[patent_app_country] => US
[patent_app_date] => 2020-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 10
[patent_no_of_words] => 48442
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16806819
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/806819 | Crystalline forms of therapeutic compounds and uses thereof | Mar 1, 2020 | Issued |